CAMP4 Therapeutics (NASDAQ:CAMP) Shares Pass Above 200 Day Moving Average – What’s Next?

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.32 and traded as high as $5.18. CAMP4 Therapeutics shares last traded at $4.90, with a volume of 128,474 shares changing hands.

Wall Street Analyst Weigh In

Several research analysts have commented on CAMP shares. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 10th. JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Piper Sandler reissued an “overweight” rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. UBS Group set a $15.00 price target on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Finally, Weiss Ratings upgraded CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.56.

CAMP4 Therapeutics Stock Performance

The stock has a 50-day moving average of $4.11 and a two-hundred day moving average of $4.33. The company has a market cap of $282.38 million, a P/E ratio of -1.94 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The firm had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. Research analysts predict that CAMP4 Therapeutics Corporation will post -0.59 EPS for the current year.

Insider Transactions at CAMP4 Therapeutics

In related news, Director Richard A. Young purchased 16,378 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $1.65 per share, with a total value of $27,023.70. Following the acquisition, the director directly owned 186,388 shares in the company, valued at $307,540.20. The trade was a 9.63% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have bought 36,031 shares of company stock worth $59,451. 21.69% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CAMP4 Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CAMP. Jupiter Topco LLC bought a new stake in shares of CAMP4 Therapeutics during the 2nd quarter valued at about $27,581,000. Janus Henderson Group PLC increased its stake in shares of CAMP4 Therapeutics by 35.9% in the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after purchasing an additional 1,666,666 shares in the last quarter. 5AM Venture Management LLC bought a new stake in CAMP4 Therapeutics during the second quarter valued at about $25,647,928,000. Vivo Capital LLC raised its stake in CAMP4 Therapeutics by 8.3% during the 4th quarter. Vivo Capital LLC now owns 4,246,568 shares of the Wireless communications provider’s stock valued at $26,031,000 after purchasing an additional 325,000 shares during the period. Finally, Balyasny Asset Management L.P. bought a new stake in shares of CAMP4 Therapeutics during the fourth quarter valued at approximately $14,938,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.